Risks Caused by Pradaxa

When Pradaxa hit the market in 2010 as a blood thinner that should prevent strokes and unsafe coagulations of the blood, it was advertised as “safe and effective.” Doctors wrote prescription after prescription of the drug for thousands of patients around the country. Before 2011 was out, however, more than 500 people died due to complications caused directly by Pradaxa use.

The blood thinner Pradaxa could cause sudden and severe internal hemorrhaging in users. Without immediate medical attention, the bleeding event could prove fatal. A previous anticoagulant that was popular on the market – Coumadin – was manufactured with an antidote that would stop bleeding in case such a side effect occurred; Pradaxa was released to the public without any such antidote.

In 2014, Pradaxa’s manufacturer, German pharmaceutical giant Boehringer Ingelheim agreed to pay $650 million to settle a total of 4,000 lawsuits, both state and federal, that had been filed due to the drug’s dangerous side effects. The company did not accept any responsibility for the dangers of the drug, insisting that it was safe all along. The massive settlement also did not excuse Boehringer from any future lawsuits that may arise from future users or future discoveries of complications.

If you or someone you know has been affected, injured, or lost their life due to Pradaxa, contact Williams DeClark Tuschman Co., L.P.A. We have been looking into Pradaxa lawsuits and studying the groundwork and outcome of such cases. With our help, you may be able to create an individual lawsuit or opt into a mass tort. Call 419.318.0772 today for more information.

Categories:

Schedule Your Free Consultation

Consultations are provided free of charge, so take this chance to get answers to your questions, straight from a team of experienced and trusted advocates. We are ready to serve you.

    • Please enter your name.
    • This isn't a valid phone number.
      Please enter your phone number.
    • This isn't a valid email address.
      Please enter your email address.
    • Please make a selection.
    • Please enter a message.